دورية أكاديمية
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
| العنوان: | Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. |
|---|---|
| المؤلفون: | Richardson, Debra L, Moore, Kathleen N, Vergote, Ignace, Gilbert, Lucy, Martin, Lainie P, Mantia-Smaldone, Gina M, Castro, Cesar M, Provencher, Diane, Matulonis, Ursula A, Stec, James, Wang, Yuemei, Method, Michael, O'Malley, David M |
| المصدر: | Gynecol Oncol ; ISSN:1095-6859 ; Volume:185 |
| بيانات النشر: | Elsevier Science |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| مصطلحات موضوعية: | Antibody-drug conjugate, Clinical trial, Combination therapy, Folate receptor alpha, Mirvetuximab soravtansine, Platinum-sensitive ovarian cancer |
| الوصف: | Evaluate the antitumor activity and safety profile of the triplet combination of mirvetuximab soravtansine (MIRV), carboplatin, and bevacizumab in recurrent, platinum-sensitive ovarian cancer. |
| نوع الوثيقة: | article in journal/newspaper report |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1016/j.ygyno.2024.01.045Test; https://pubmed.ncbi.nlm.nih.gov/38447347Test |
| DOI: | 10.1016/j.ygyno.2024.01.045 |
| الإتاحة: | https://doi.org/10.1016/j.ygyno.2024.01.045Test https://pubmed.ncbi.nlm.nih.gov/38447347Test |
| حقوق: | Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. |
| رقم الانضمام: | edsbas.F7F91611 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.ygyno.2024.01.045 |
|---|